Skip to main content
Have a personal or library account? Click to login
Overview of Restrictive Cardiomyopathies Cover
Open Access
|Mar 2022

References

  1. Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008 Jan;29(2):270-6. doi: 10.1093/eurheartj/ehm342
  2. McKenna WJ, Maron BJ, Thiene G. Classification, Epidemiology, and Global Burden of Cardiomyopathies. Circ Res. 2017 Sep 15;121(7):722-730. doi: 10.1161/CIRCRESAHA.117.309711
  3. Pereira NL, Grogan M, Dec GW. Spectrum of Restrictive and Infiltrative Cardiomyopathies: Part 1 of a 2-Part Series. J Am Coll Cardiol. 2018 Mar 13;71(10):1130-1148. doi: 10.1016/j.jacc.2018.01.016
  4. Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med. 1997 Jan 23;336(4):267-76. doi: 10.1056/NEJM199701233360407
  5. Garcia MJ. Constrictive Pericarditis Versus Restrictive Cardiomyopathy? J Am Coll Cardiol. 2016 May 3;67(17):2061-76. doi: 10.1016/j.jacc.2016.01.076
  6. Geske JB, Anavekar NS, Nishimura RA, Oh JK, Gersh BJ. Differentiation of Constriction and Restriction: Complex Cardiovascular Hemodynamics. J Am Coll Cardiol. 2016 Nov 29;68(21):2329-2347. doi: 10.1016/j.jacc.2016.08.050
  7. Galea N, Polizzi G, Gatti M, Cundari G, Figuera M, Faletti R. Cardiovascular magnetic resonance (CMR) in restrictive cardiomyopathies. Radiol Med. 2020 Nov;125(11):1072-1086. doi: 10.1007/s11547-020-01287-8
  8. Elliott P, Arbustini E. The role of endomyocardial biopsy in the management of cardiovascular disease: a commentary on joint AHA/ACC/ESC guidelines. Heart. 2009 May;95(9):759-60. doi: 10.1136/hrt.2008.161166
  9. Casella M, Dello Russo A, Bergonti M, et al. Diagnostic Yield of Electroanatomic Voltage Mapping in Guiding Endomyocardial Biopsies. Circulation. 2020 Sep 29;142(13):1249-1260. doi: 10.1161/CIRCULATIONAHA.120.046900
  10. Rai TS, Ahmad S, Ahluwalia TS, et al. Genetic and clinical profile of Indian patients of idiopathic restrictive cardiomyopathy with and without hypertrophy. Mol Cell Biochem. 2009 Nov;331(1-2):187-92. doi: 10.1007/s11010-009-0157-7
  11. Anderson HN, Cetta F, Driscoll DJ, Olson TM, Ackerman MJ, Johnson JN. Idiopathic Restrictive Cardiomyopathy in Children and Young Adults. Am J Cardiol. 2018 May 15;121(10):1266-1270. doi: 10.1016/j.amjcard.2018.01.045
  12. Ammash NM, Seward JB, Bailey KR, Edwards WD, Tajik AJ. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation. 2000 May 30;101(21):2490-6. doi: 10.1161/01.cir.101.21.2490
  13. Gujja P, Rosing DR, Tripodi DJ, Shizukuda Y. Iron overload cardiomyopathy: better understanding of an increasing disorder. J Am Coll Cardiol. 2010 Sep 21;56(13):1001-12. doi: 10.1016/j.jacc.2010.03.083
  14. Crownover BK, Covey CJ. Hereditary hemochromatosis. Am Fam Physician. 2013 Feb 1;87(3):183-90.
  15. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasing global health problem. Bull World Health Organ. 2001;79(8):704-12.
  16. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med. 1994 Sep 1;331(9):574-8. doi: 10.1056/NEJM199409013310903
  17. Liu P, Olivieri N. Iron overload cardiomyopathies: new insights into an old disease. Cardiovasc Drugs Ther. 1994 Feb;8(1):101-10. doi: 10.1007/BF00877096
  18. Buja LM, Roberts WC. Iron in the heart. Etiology and clinical significance. Am J Med. 1971 Aug;51(2):209-21. doi: 10.1016/0002-9343(71)90240-3
  19. Horwitz LD, Rosenthal EA. Iron-mediated cardiovascular injury. Vasc Med. 1999;4(2):93-9. doi: 10.1177/1358836X9900400207
  20. Bacon BR, Adams PC, Kowdley KV, Powell LW, Tavill AS. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011 Jul;54(1):328-43. doi: 10.1002/hep.24330
  21. Kremastinos DT, Tsiapras DP, Tsetsos GA, Rentoukas EI, Vretou HP, Toutouzas PK. Left ventricular diastolic Doppler characteristics in beta-thalassemia major. Circulation. 1993 Sep;88(3):1127-35. doi: 10.1161/01.cir.88.3.1127
  22. Wood JC. Use of magnetic resonance imaging to monitor iron overload. Hematol Oncol Clin North Am. 2014 Aug;28(4):747-64, vii. doi: 10.1016/j.hoc.2014.04.002
  23. Kremastinos DT, Farmakis D. Iron overload cardiomyopathy in clinical practice. Circulation. 2011 Nov 15;124(20):2253-63. doi: 10.1161/CIRCULATIONAHA.111.050773
  24. Caines AE, Kpodonu J, Massad MG, et al. Cardiac transplantation in patients with iron overload cardiomyopathy. J Heart Lung Transplant. 2005 Apr;24(4):486-8. doi: 10.1016/j.healun.2004.02.009
  25. Morrissey RP, Philip KJ, Schwarz ER. Cardiac abnormalities in Anderson-Fabry disease and Fabry’s cardiomyopathy. Cardiovasc J Afr. Jan-Feb 2011;22(1):38-44.
  26. Mocumbi AO, Stothard JR, Correia-de-Sá P, Yacoub M. Endomyocardial Fibrosis: an Update After 70 Years. Curr Cardiol Rep. 2019 Nov 22;21(11):148. doi: 10.1007/s11886-019-1244-3
  27. Grimaldi A, Mocumbi AO, Freers J, et al. Tropical Endomyocardial Fibrosis: Natural History, Challenges, and Perspectives. Circulation. 2016 Jun 14;133(24):2503-15. doi: 10.1161/CIRCULATIONAHA.115.021178
  28. Nwokolo C. The evolution of endomyocardial fibrosis. West Afr Med J. 1962 Apr;11:51-7.
  29. Duraes AR, de Souza Lima Bitar Y, Roever L, Neto MG. Endomyocardial fibrosis: past, present, and future. Heart Fail Rev. 2020 Sep;25(5):725-730. doi: 10.1007/s10741-019-09848-4
  30. Barretto AC, Mady C, Nussbacher A, et al. Atrial fibrillation in endomyocardial fibrosis is a marker of worse prognosis. Int J Cardiol. 1998 Nov 30;67(1):19-25. doi: 10.1016/s0167-5273(98)00228-9
  31. León D, Martín M, Corros C, Santamarta E, Costilla S, Lambert JL. Usefulness of cardiac MRI in the early diagnosis of endomyocardial fibrosis. Rev Port Cardiol. 2012 May;31(5):401-2. doi: 10.1016/j.repc.2011.12.016
  32. Ogbogu PU, Rosing DR, Horne MK 3rd. Cardiovascular manifestations of hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007 Aug;27(3):457-75. doi: 10.1016/j.iac.2007.07.001
  33. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994 May 15;83(10):2759-79.
  34. Ommen SR, Seward JB, Tajik AJ. Clinical and echocardiographic features of hypereosinophilic syndromes. Am J Cardiol. 2000 Jul 1;86(1):110-3. doi: 10.1016/s0002-9149(00)00841-9
  35. Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood. 2006 Jan 15;107(2):558-65. doi: 10.1182/blood-2005-05-2152
  36. Salanitri GC. Endomyocardial fibrosis and intracardiac thrombus occurring in idiopathic hypereosinophilic syndrome. AJR Am J Roentgenol. 2005 May;184(5):1432-3. doi: 10.2214/ajr.184.5.01841432
  37. Plastiras SC, Economopoulos N, Kelekis NL, Tzelepis GE. Magnetic resonance imaging of the heart in a patient with hypereosinophilic syndrome. Am J Med. 2006 Feb;119(2):130-2. doi: 10.1016/j.amjmed.2005.10.055
  38. Klion AD. How I treat hypereosinophilic syndromes. Blood. 2015 Aug 27;126(9):1069-77. doi: 10.1182/blood-2014-11-551614
  39. Moraes F, Lapa C, Hazin S, Tenorio E, Gomes C, Moraes CR. Surgery for endomyocardial fibrosis revisited. Eur J Cardiothorac Surg. 1999 Mar;15(3):309-12; discussion 312-3. doi: 10.1016/s1010-7940(99)00027-5
  40. Tselios K, Deeb M, Gladman DD, Harvey P, Urowitz MB. Antimalarial-induced cardiomyopathy: a systematic review of the literature. Lupus. 2018 Apr;27(4):591-599. doi: 10.1177/0961203317734922
  41. Yusuf SW, Sami S, Daher IN. Radiation-induced heart disease: a clinical update. Cardiol Res Pract. 2011 Feb 27;2011:317659. doi: 10.4061/2011/317659
  42. Madan R, Benson R, Sharma DN, Julka PK, Rath GK. Radiation induced heart disease: Pathogenesis, management and review literature. J Egypt Natl Canc Inst. 2015 Dec;27(4):187-93. doi: 10.1016/j.jnci.2015.07.005
  43. Zamorano JL, Lancellotti P, Rodriguez Muñoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016 Sep 21;37(36):2768-2801. doi: 10.1093/eurheartj/ehw211
  44. Al-Kindi SG, Oliveira GH. Heart Transplantation Outcomes in Radiation-Induced Restrictive Cardiomyopathy. J Card Fail. 2016 Jun;22(6):475-8. doi: 10.1016/j.cardfail.2016.03.014
DOI: https://doi.org/10.14797/mdcvj.1078 | Journal eISSN: 1947-6108
Language: English
Page range: 4 - 16
Submitted on: Jan 3, 2022
Accepted on: Feb 10, 2022
Published on: Mar 14, 2022
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services

© 2022 Smitha Narayana Gowda, Hyeon-Ju Ali, Imad Hussain, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.